1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Ladaviere, L.
Deleage, G.
Montserret, R.
Dalbon, P.
Jolivet, M.
Penin, F.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Structural Analysis of the Immunodominant Antigenic Region of the Hepatitis C Virus Capsid Protein by NMR
10.2210/pdb1cwx/pdb
pdb_00001cwx
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
4909.684
HEPATITIS C VIRUS CAPSID PROTEIN
N-TERMINAL FRAGMENT
1
syn
polymer
no
no
STNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLG
STNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLG
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
1999-08-30
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
RCSB
Y
RCSB
1999-08-27
REL
REL
THE PROTEIN WAS CHEMICALLY SYNTHESIZED. THIS SEQUENCE OCCURS NATURALLY IN HEPATITIS C VIRUS (GENOTYPE 1A ISOLATE H77)..
sample
THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES.
MOST CONVERGENT STRUCTURES AT THE LEVEL OF BOTH HELICES. NOTE THAT 23
STRUCTURES OVER 50 HAD NO RESTRAINT VIOLATION > 0.5 ANGSTROM.
50
4
2D NOESY
DQF-COSY
2D ROESY
2D TOCSY
0.1M NACL
5.9
AMBIENT
293
K
DISTANCE GEOMETRY SIMULATED ANNEALING MOLECULAR DYNAMICS MATRIX RELAXATION
4
closest to the average
40% D2-TRIFLUOROETHANOL;0.01M SODIUM PHOSPHATE;0.1M NACL
VARIAN
collection
VNMR
5.1
VARIAN
data analysis
VNMR
5.1
BRUNGER
refinement
X-PLOR
3.1
BRUNGER
structure solution
X-PLOR
3.1
500
Varian
UNITYPLUS
SER
1
n
1
SER
1
A
THR
2
n
2
THR
2
A
ASN
3
n
3
ASN
3
A
PRO
4
n
4
PRO
4
A
LYS
5
n
5
LYS
5
A
PRO
6
n
6
PRO
6
A
GLN
7
n
7
GLN
7
A
ARG
8
n
8
ARG
8
A
LYS
9
n
9
LYS
9
A
THR
10
n
10
THR
10
A
LYS
11
n
11
LYS
11
A
ARG
12
n
12
ARG
12
A
ASN
13
n
13
ASN
13
A
THR
14
n
14
THR
14
A
ASN
15
n
15
ASN
15
A
ARG
16
n
16
ARG
16
A
ARG
17
n
17
ARG
17
A
PRO
18
n
18
PRO
18
A
GLN
19
n
19
GLN
19
A
ASP
20
n
20
ASP
20
A
VAL
21
n
21
VAL
21
A
LYS
22
n
22
LYS
22
A
PHE
23
n
23
PHE
23
A
PRO
24
n
24
PRO
24
A
GLY
25
n
25
GLY
25
A
GLY
26
n
26
GLY
26
A
GLY
27
n
27
GLY
27
A
GLN
28
n
28
GLN
28
A
ILE
29
n
29
ILE
29
A
VAL
30
n
30
VAL
30
A
GLY
31
n
31
GLY
31
A
GLY
32
n
32
GLY
32
A
VAL
33
n
33
VAL
33
A
TYR
34
n
34
TYR
34
A
LEU
35
n
35
LEU
35
A
LEU
36
n
36
LEU
36
A
PRO
37
n
37
PRO
37
A
ARG
38
n
38
ARG
38
A
ARG
39
n
39
ARG
39
A
GLY
40
n
40
GLY
40
A
PRO
41
n
41
PRO
41
A
ARG
42
n
42
ARG
42
A
LEU
43
n
43
LEU
43
A
GLY
44
n
44
GLY
44
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
ARG
8
0.318
SIDE CHAIN
1
A
ARG
12
0.309
SIDE CHAIN
1
A
ARG
16
0.289
SIDE CHAIN
1
A
ARG
17
0.239
SIDE CHAIN
1
A
ARG
38
0.305
SIDE CHAIN
1
A
ARG
39
0.241
SIDE CHAIN
1
A
ARG
42
0.285
SIDE CHAIN
2
A
ARG
8
0.310
SIDE CHAIN
2
A
ARG
12
0.270
SIDE CHAIN
2
A
ARG
16
0.084
SIDE CHAIN
2
A
ARG
17
0.263
SIDE CHAIN
2
A
ARG
38
0.299
SIDE CHAIN
2
A
ARG
39
0.196
SIDE CHAIN
2
A
ARG
42
0.298
SIDE CHAIN
3
A
ARG
8
0.254
SIDE CHAIN
3
A
ARG
12
0.230
SIDE CHAIN
3
A
ARG
16
0.310
SIDE CHAIN
3
A
ARG
17
0.191
SIDE CHAIN
3
A
ARG
38
0.273
SIDE CHAIN
3
A
ARG
39
0.200
SIDE CHAIN
3
A
ARG
42
0.315
SIDE CHAIN
4
A
ARG
8
0.317
SIDE CHAIN
4
A
ARG
12
0.311
SIDE CHAIN
4
A
ARG
17
0.225
SIDE CHAIN
4
A
ARG
38
0.315
SIDE CHAIN
4
A
ARG
39
0.294
SIDE CHAIN
4
A
ARG
42
0.249
SIDE CHAIN
1
A
THR
2
-179.90
89.37
1
A
LYS
5
164.29
-51.52
1
A
LYS
9
179.45
-49.94
1
A
THR
10
-85.71
-80.39
1
A
ARG
12
63.23
-174.80
1
A
ASN
13
-45.02
169.28
1
A
THR
14
-173.66
-38.29
1
A
ARG
17
120.76
-45.57
1
A
GLN
19
-86.71
41.26
1
A
ASP
20
-155.39
-43.16
1
A
GLN
28
-48.14
-10.28
1
A
ILE
29
80.37
-6.72
1
A
ARG
39
-52.77
94.09
2
A
THR
2
59.98
-89.01
2
A
ASN
3
-164.66
84.54
2
A
LYS
9
-173.71
149.65
2
A
LYS
11
-173.05
-53.35
2
A
ARG
12
61.86
129.09
2
A
THR
14
-170.67
-43.55
2
A
ASN
15
-164.65
116.25
2
A
ARG
17
161.42
-57.26
2
A
GLN
19
-91.27
43.99
2
A
ASP
20
-151.52
-39.98
2
A
PRO
24
-77.21
-72.97
2
A
ILE
29
83.26
-12.09
2
A
ARG
38
-87.58
39.25
3
A
ASN
3
-176.65
96.18
3
A
LYS
9
-150.93
-90.03
3
A
THR
10
79.96
-73.36
3
A
LYS
11
62.59
127.95
3
A
ARG
12
50.47
-179.69
3
A
ASN
13
-149.98
-66.37
3
A
ARG
17
147.93
-57.96
3
A
GLN
19
-89.49
40.60
3
A
ASP
20
-153.89
-43.06
3
A
ARG
39
-50.06
96.19
4
A
THR
2
-157.98
-74.63
4
A
LYS
5
61.44
79.68
4
A
GLN
7
-75.83
-90.04
4
A
ARG
8
-174.09
99.75
4
A
LYS
9
-163.13
-88.10
4
A
THR
10
174.71
172.92
4
A
LYS
11
-58.20
177.77
4
A
ASN
15
-47.39
92.84
4
A
ARG
17
124.49
-47.50
4
A
GLN
19
-89.37
44.80
4
A
ASP
20
-157.26
-41.81
4
A
GLN
28
-135.95
-33.67
4
A
ILE
29
85.34
-12.95
4
A
PRO
37
-77.22
-100.62
4
A
ARG
38
-94.72
-106.04
4
A
LEU
43
-118.71
61.15
SOLUTION STRUCTURE OF THE HEPATITIS C VIRUS N-TERMINAL CAPSID PROTEIN 2-45 [C-HCV(2-45)]
1
N
N
VIRAL PROTEIN
HELIX-LOOP-HELIX, Viral protein
POLG_HCVH
UNP
1
P27958
2
45
1CWX
1
44
P27958
A
1
1
44
1
P 1